title: Clinical experience with chemoradiotherapy comprising S-1 plus low-dose cisplatin in a patient with stage IV anal cancer.
abstract: We report a case of anal cancer in a 58-year-old woman who complained of narrow, bloody stools and anal pain. Physical examination revealed anal stenosis associated with a circular mass arising in the anal canal. Histological examination of biopsy specimens confirmed a diagnosis of moderately differentiated squamous cell carcinoma. Enhanced computed tomography revealed anal cancer invading the levator ani and the vagina, with lymph-node, multiple hepatic, and pulmonary metastases. The patient received two cycle of chemoradiotherapy with S-1 plus low-dose cisplatin with rest for 4 weeks, leading to complete response of the primary lesion and a partial response of the metastatic lesions. Each cycle included oral S-1 (120 mg/body; day 1-21), cisplatin (10 mg/body; day 1-5, 8-12) and radiotherapy (2 Gy/day; day 1-5, 8-12, 15-19). Adverse effects of treatment were mild perineal skin erosion and mild appetite loss, but no hematologic toxicity. Although the patient died 16 months after first admission, chemoradiotherapy with S-1 plus cisplatin is potentially effective for the management of advanced anal cancer.
authors: Department of Surgery, International University of Health and Welfare, Mita Hospital, Mita 1-4-3, Minato-ku, Tokyo, Japan. nnitori@iuhw.ac.jp
authors: Nobuhiro
authors: N
authors: Nitori
authors: Yutaro
authors: Y
authors: Kato
authors: Ayu
authors: A
authors: Kato
authors: Tomoaki
authors: T
authors: Deguchi
authors: Akihiro
authors: A
authors: Okada
authors: Masayuki
authors: M
authors: Kojima
authors: Junko
authors: J
authors: Kuroda
authors: Tomohisa
authors: T
authors: Kadomura
authors: Keisuke
authors: K
authors: Kubota
authors: Nobuto
authors: N
authors: Origuchi
authors: Masato
authors: M
authors: Fujisaki
authors: Masaki
authors: M
authors: Kitajima
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001005:Anus Neoplasms / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D004338:Drug Combinations; D005260:Female; D005720:Gamma Rays; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy*; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy*; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin